Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.46 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.46 |
| ▸ | CTSA | P10619 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31697139 | 1.00 | KDM4E (0.48) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL22208625 | 0.91 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL31697082 | 0.91 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL29786753 | 0.89 | SCN8A (0.48) | GPBAR1AKR1C3AKR1C2SCN8ASCN10A | |
| SCHEMBL22208882 | 0.88 | CFTR (0.51) | KDM4EALDH1A1HPGDGPBAR1AKR1C3 | |
| SCHEMBL31697102 | 0.88 | CFTR (0.51) | KDM4EALDH1A1HPGDGPBAR1AKR1C3 | |
| SCHEMBL22208780 | 0.82 | CFTR (0.53) | KDM4EALDH1A1HPGDGPBAR1AKR1C3 | |
| SCHEMBL31697222 | 0.82 | CFTR (0.53) | KDM4EALDH1A1HPGDGPBAR1AKR1C3 | |
| SCHEMBL22853079 | 0.81 | MPO (0.57) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL30294712 | 0.81 | MPO (0.57) | KDM4EALDH1A1HPGDHSD17B10USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441703-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-10-14 | — | — | US | disclosed |
| US-20230062053-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2023-03-02 | — | — | US | disclosed |
| US-20230062053-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2023-03-02 | — | — | US | disclosed |
| WO-2020146682-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020146682-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441703-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | KDM4E 1582/4885ALDH1A1 2665/4885HPGD 1512/4885 |
| US-20230062053-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | KDM4E 1582/4885ALDH1A1 2665/4885HPGD 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.